Status:

COMPLETED

Immune Adsorption Role in Treatment of Resistant Lupus

Lead Sponsor:

Dr. Mohamed Ahmed El ghiriani

Conditions:

Systemic Lupus

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

Background: lupus is a heterogeneous autoimmune disease with autoantibodies formation. Lupus nephritis carries the worst prognosis. C1q deficiency correlates with activity and renal involvement and ma...

Detailed Description

Settings and design: A controlled clinical study was conducted on group A, sixty patients with lupus in activity subdivided into cases 1, 47 patients, who received traditional medical treatment and ca...

Eligibility Criteria

Inclusion

  • systemic lupus erythematosus in activity

Exclusion

  • End stage renal disease, other renal replacement therapy

Key Trial Info

Start Date :

January 1 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 25 2019

Estimated Enrollment :

90 Patients enrolled

Trial Details

Trial ID

NCT04108611

Start Date

January 1 2019

End Date

September 25 2019

Last Update

October 1 2019

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Faculty of Medicine Alexandria University

Alexandria, Sidi Beshr, Egypt, 21624

Immune Adsorption Role in Treatment of Resistant Lupus | DecenTrialz